Acadian Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-7,155
| Closed | -$3K | – | 1860 |
|
|
2024
Q4 | $3K | Hold |
7,155
| – | – | ﹤0.01% | 1575 |
|
|
2024
Q3 | $26K | Sell |
7,155
-19,235
| -73% | -$91.8K | ﹤0.01% | 1941 |
|
|
2024
Q2 | $147K | Sell |
26,390
-26,056
| -50% | -$113K | ﹤0.01% | 1484 |
|
|
2024
Q1 | $274K | Sell |
52,446
-235,109
| -82% | -$1.29M | ﹤0.01% | 1130 |
|
|
2023
Q4 | $1.5M | Buy |
287,555
+50,653
| +21% | +$500K | 0.01% | 747 |
|
|
2023
Q3 | $3.73M | Buy |
236,902
+12,326
| +5% | +$221K | 0.02% | 527 |
|
|
2023
Q2 | $4.36M | Buy |
224,576
+9,145
| +4% | +$217K | 0.02% | 491 |
|
|
2023
Q1 | $6.11M | Sell |
215,431
-16,156
| -7% | -$480K | 0.03% | 410 |
|
|
2022
Q4 | $6.76M | Sell |
231,587
-79,633
| -26% | -$2.53M | 0.03% | 370 |
|
|
2022
Q3 | $8.22M | Buy |
311,220
+124,347
| +67% | +$4.56M | 0.05% | 307 |
|
|
2022
Q2 | $8.3M | Buy |
186,873
+47,178
| +34% | +$2.17M | 0.04% | 305 |
|
|
2022
Q1 | $6.91M | Buy |
139,695
+33,816
| +32% | +$1.62M | 0.03% | 391 |
|
|
2021
Q4 | $5.39M | Sell |
105,879
-23,551
| -18% | -$1.22M | 0.02% | 438 |
|
|
2021
Q3 | $7.21M | Sell |
129,430
-132,273
| -51% | -$6.51M | 0.03% | 374 |
|
|
2021
Q2 | $11.2M | Buy |
261,703
+48,694
| +23% | +$2.01M | 0.04% | 307 |
|
|
2021
Q1 | $8.89M | Buy |
213,009
+41,525
| +24% | +$1.93M | 0.03% | 349 |
|
|
2020
Q4 | $7.99M | Buy |
171,484
+2,785
| +2% | +$130K | 0.03% | 389 |
|
|
2020
Q3 | $7.17M | Buy |
168,699
+50,643
| +43% | +$2.22M | 0.03% | 367 |
|
|
2020
Q2 | $5.66M | Buy |
118,056
+30,043
| +34% | +$1.5M | 0.02% | 462 |
|
|
2020
Q1 | $4.05M | Buy |
88,013
+64,413
| +273% | +$3.23M | 0.02% | 434 |
|
|
2019
Q4 | $1.42M | Sell |
23,600
-6,893
| -23% | -$411K | 0.01% | 791 |
|
|
2019
Q3 | $1.73M | Sell |
30,493
-4,380
| -13% | -$246K | 0.01% | 727 |
|
|
2019
Q2 | $1.94M | Buy |
34,873
+30,725
| +741% | +$1.6M | 0.01% | 627 |
|
|
2019
Q1 | $210K | Buy |
4,148
+1,140
| +38% | +$50.7K | ﹤0.01% | 1346 |
|
|
2018
Q4 | $121K | Buy |
3,008
+1,356
| +82% | +$69.9K | ﹤0.01% | 1234 |
|
|
2018
Q3 | $115K | Buy |
+1,652
| New | +$125K | ﹤0.01% | 1178 |
|
|
2018
Q1 | – | Sell |
-3,761
| Closed | -$201K | – | 1871 |
|
|
2017
Q4 | $201K | Sell |
3,761
-3,876
| -51% | -$216K | ﹤0.01% | 952 |
|
|
2017
Q3 | $456K | Buy |
+7,637
| New | +$462K | ﹤0.01% | 799 |
|
Other funds holding EGRX
Acadian Asset Management's EGRX Position: Q1 2025 in Review
Acadian Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2025, closing a stake of 7,155 shares — an estimated $3K sold.
Acadian Asset Management first reported a position in EGRX in Q3 2017 and held it in 28 quarters. The position peaked at $11.2M in Q2 2021. 2 funds tracked by Wall St. Rank hold EGRX as of Q1 2025.
- Acadian Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2025 after selling out during the quarter.
- Acadian Asset Management sold 7,155 Eagle Pharmaceuticals, Inc. shares in Q1 2025, an estimated $3K.
- Acadian Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 28 quarters.
- Acadian Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $11.2M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2025.
Based on Acadian Asset Management's 13F filing for Q1 2025, filed 21 May 2025.